Mark S George1, Joseph J Taylor, E Baron Short. 1. Psychiatry Department, Brain Stimulation Laboratory, Medical University of South Carolina, and Ralph H. Johnson VA Medical Center, Charleston, South Carolina 29425, USA. georgem@musc.edu
Abstract
PURPOSE OF REVIEW: Daily left prefrontal transcranial magnetic stimulation (TMS) for several weeks was first proposed as an acute treatment for depression in the early 1990s, and was Food and Drug Administration (FDA) approved in 2008. In the past year, several important studies have been published that extend our understanding of this novel treatment approach. RECENT FINDINGS: The first round of multisite clinical trials with TMS addressed whether prefrontal rTMS has efficacy and were conducted in carefully selected depressed patients who were antidepressant medication free. Several more recent studies assess the clinical effectiveness of TMS and report that about 35-40% of real-world patients who are commonly taking adjunctive antidepressants reach remission with a modest side effect profile. There are also new studies examining the durability of the TMS-induced antidepressant effect. Fifty-eight percent of TMS remitters remain remitted at 3-month follow-up. SUMMARY: These recent studies suggest that daily left prefrontal TMS over several weeks as a treatment for depression not only appears to have efficacy in rigorous randomized controlled trials, but is effective in real-world settings, with remission in 30-40% of patients. The TMS antidepressant effect, once achieved, appears to be as durable as with other antidepressant medications or interventions. Much more research is needed, particularly with issues such as the TMS coil location, stimulation intensity and frequency, and dosing strategy.
PURPOSE OF REVIEW: Daily left prefrontal transcranial magnetic stimulation (TMS) for several weeks was first proposed as an acute treatment for depression in the early 1990s, and was Food and Drug Administration (FDA) approved in 2008. In the past year, several important studies have been published that extend our understanding of this novel treatment approach. RECENT FINDINGS: The first round of multisite clinical trials with TMS addressed whether prefrontal rTMS has efficacy and were conducted in carefully selected depressedpatients who were antidepressant medication free. Several more recent studies assess the clinical effectiveness of TMS and report that about 35-40% of real-world patients who are commonly taking adjunctive antidepressants reach remission with a modest side effect profile. There are also new studies examining the durability of the TMS-induced antidepressant effect. Fifty-eight percent of TMS remitters remain remitted at 3-month follow-up. SUMMARY: These recent studies suggest that daily left prefrontal TMS over several weeks as a treatment for depression not only appears to have efficacy in rigorous randomized controlled trials, but is effective in real-world settings, with remission in 30-40% of patients. The TMS antidepressant effect, once achieved, appears to be as durable as with other antidepressant medications or interventions. Much more research is needed, particularly with issues such as the TMS coil location, stimulation intensity and frequency, and dosing strategy.
Authors: M S George; T A Ketter; P I Parekh; N Rosinsky; H A Ring; P J Pazzaglia; L B Marangell; A M Callahan; R M Post Journal: J Neuropsychiatry Clin Neurosci Date: 1997 Impact factor: 2.198
Authors: M S George; T A Ketter; P I Parekh; N Rosinsky; H Ring; B J Casey; M R Trimble; B Horwitz; P Herscovitch; R M Post Journal: Hum Brain Mapp Date: 1994 Impact factor: 5.038
Authors: V Di Lazzaro; F Pilato; E Saturno; A Oliviero; M Dileone; P Mazzone; A Insola; P A Tonali; F Ranieri; Y Z Huang; J C Rothwell Journal: J Physiol Date: 2005-04-21 Impact factor: 5.182
Authors: H S Mayberg; M Liotti; S K Brannan; S McGinnis; R K Mahurin; P A Jerabek; J A Silva; J L Tekell; C C Martin; J L Lancaster; P T Fox Journal: Am J Psychiatry Date: 1999-05 Impact factor: 18.112
Authors: William M McDonald; Valerie Durkalski; Edward R Ball; Paul E Holtzheimer; Martina Pavlicova; Sarah H Lisanby; David Avery; Berry S Anderson; Ziad Nahas; Paul Zarkowski; Harold A Sackeim; Mark S George Journal: Depress Anxiety Date: 2011-09-02 Impact factor: 6.505
Authors: T A Ketter; P J Andreason; M S George; C Lee; D S Gill; P I Parekh; M W Willis; P Herscovitch; R M Post Journal: Arch Gen Psychiatry Date: 1996-01
Authors: Jerome A Yesavage; J Kaci Fairchild; Zhibao Mi; Kousick Biswas; Anne Davis-Karim; Ciaran S Phibbs; Steven D Forman; Michael Thase; Leanne M Williams; Amit Etkin; Ruth O'Hara; Gerald Georgette; Tamara Beale; Grant D Huang; Art Noda; Mark S George Journal: JAMA Psychiatry Date: 2018-09-01 Impact factor: 21.596
Authors: Joseph J Taylor; Daniel J Neitzke; George Khouri; Jeffrey J Borckardt; Ron Acierno; Peter W Tuerk; Matthew Schmidt; Mark S George Journal: Psychiatry Res Date: 2014-06-16 Impact factor: 3.222
Authors: Jennifer Barredo; John A Bellone; Melissa Edwards; Linda L Carpenter; Stephen Correia; Noah S Philip Journal: Depress Anxiety Date: 2019-09-02 Impact factor: 6.505
Authors: Sung Wook Chung; Nigel C Rogasch; Kate E Hoy; Caley M Sullivan; Robin F H Cash; Paul B Fitzgerald Journal: Hum Brain Mapp Date: 2017-11-09 Impact factor: 5.038